Sienna Cancer Diagnostics Ltd. announced the appointment of Zotal Ltd. ("Zotal") as its exclusive distributor in Israel. The distribution agreement provides Zotal with the right to sell Sienna's hTERT IVD to pathology laboratories where it will be used to assist in the diagnosis of bladder cancer. With a population of approximately 9 million, Israel has a growing elderly demographic with a need for easy, accessible, affordable diagnostics. Sienna and Zotal will now focus on the product registration and reimbursement applications with the Department of Medical Devices, Ministry of Health (MOH), in Israel, which is expected to take approximately 6 months. In addition to providing regulatory support, Sienna will provide sales, marketing, and technical training to Zotal staff, while Zotal will source several reference laboratories to assist in the adoption of the test in Israel. This process is vital for unique products such as hTERT which require time to educate the market before initial market adoption occurs.